⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Myostatin/Activin Pathway Inhibitors
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-11-11 — Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial.: [human-rct] The phase 2 double-blind placebo-controlled COURAGE RCT (n=975) provides human proof of concept for trevogrumab-mediated myostatin inhibition to attenuate lean-mass loss during semaglutide treatment in adults with obesity, while the trevogrumab–garetosmab combination improved body composition further but caused unacceptable adverse events, separating selective GDF8 inhibition from dual GDF8/activin A blockade without establishing strength, disability, or longevity benefits. [human-rct] (novelty: 4)
- 2026-10-03 — Myostatin inhibitors and the paradox of larger but weaker muscles: cross-connection with myostatin-inhibitors: Near-duplicate scope; Attia’s mass-without-strength paradox applies to both pages and suggests they should be reconciled or cross-linked. (novelty: 3)
- 2026-09-27 — Discovery of Fisetin as a potent and cell-active ACVR2A inhibitor.: cross-connection with fisetin: Fisetin now has a reported small-molecule ACVR2A-inhibitory activity, placing a dietary flavonoid in the same target class as biologic myostatin/activin blockers — same pathway, very different potency and delivery assumptions. (novelty: 3)
- 2026-09-16 — RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients: cross-connection with rankl-inhibitors: Parallel clinical bets on sarcopenia in fracture/older populations from very different mechanistic angles — bone-remodeling axis vs. direct muscle-growth pathway. (novelty: 3)
- 2026-09-18 — RANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis: cross-connection with denosumab-rankl: Parallel pharmacologic strategies for sarcopenia targeting distinct pathways (RANKL vs. myostatin/activin) in older adults with muscle loss. (novelty: 3)
Open questions
Related
Contributing findings
Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial.
11-nov-2026
novelty 4
per-area 4
strengthens
Targeting skeletal muscle wasting: Emerging therapeutics and translational challenges.
10-sep-2026
novelty 2
per-area 2
strengthens